Merck & Co. Gets FDA Nod to Manufacture Bulk Vaccine at North Carolina Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck & Co. Gets FDA Nod to Manufacture Bulk Vaccine at North Carolina Facility


Merck & Co. has received FDA approval to manufacture bulk varicella, used in in Merck’s vaccines to protect against chickenpox and shingles, at the company’s site in Durham, North Carolina. The approval will enable the site to produce bulk varicella supply for the United States  and help boost Merck’s overall global supply capabilities.

In 2010, the site was approved to produce finished chickenpox vaccines. In the longer term, Merck plans for the site to produce bulk and finished product for other Merck childhood vaccines and for its shingles vaccines, according to a Sept. 4, 2013 Merck press release.

Prior to this licensure, all global bulk supplies for Merck’s varicella-containing vaccines were produced at the company’s facility in West Point, Pennsylvania. The Durham facility is part of Merck’s more than $1-billion investment in its vaccine-manufacturing capabilities during the past nine years. The company also modernized and expanded vaccine operations at its facilities in West Point, Pennsylvania and Elkton, Virginia and built a new facility in Carlow, Ireland, which is scheduled to be licensed in 2014. Merck broke ground for the Durham site in 2004.

Source: Merck & Co.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here